(Q36895534)

16 August 2017

1 reference

title

Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives (English)

1 reference

16 August 2017

0 references

1 reference

1

Hans-Jürgen Möller

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

67

1 reference

16 August 2017

issue

11

1 reference

16 August 2017

page(s)

1541-1566

1 reference

Cost of relapse in schizophrenia

16 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767110-00003

Factors related to tardive dyskinesia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767110-00003

State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics

21 January 2018

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

1 reference

12 December 2020

Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

1 reference

12 December 2020

The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms

1 reference

12 December 2020

Depot neuroleptics in relapse prevention: advantages and disadvantages.

1 reference

12 December 2020

Clinical guidelines: Dosing and switching strategies for long-acting risperidone.

1 reference

12 December 2020

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

1 reference

12 December 2020

Health resource utilization associated with switching to risperidone long-acting injection

1 reference

12 December 2020

Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone

1 reference

12 December 2020

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

12 December 2020

Depot antipsychotic drugs. Place in therapy

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

1 reference

12 December 2020

Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria

1 reference

12 December 2020

Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Direct transition to long-acting risperidone--analysis of long-term efficacy

1 reference

12 December 2020

Course and long-term treatment of schizophrenic psychoses

1 reference

12 December 2020

Long-acting risperidone: a review of its use in schizophrenia

1 reference

12 December 2020

Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Prognostic indicators for early discontinuation of risperidone long-acting injection

1 reference

12 December 2020

Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia

1 reference

12 December 2020

Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine

1 reference

12 December 2020

Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients

1 reference

12 December 2020

Long-acting risperidone: focus on safety

1 reference

12 December 2020

Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia

1 reference

12 December 2020

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection

1 reference

12 December 2020

Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone

1 reference

12 December 2020

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

12 December 2020

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

1 reference

12 December 2020

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

1 reference

12 December 2020

Economic evaluations of olanzapine and risperidone.

1 reference

12 December 2020

Medication adherence of individuals with a first episode of psychosis

1 reference

12 December 2020

Risperidone: a review

1 reference

12 December 2020

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

1 reference

12 December 2020

Remission in schizophrenia: proposed criteria and rationale for consensus

1 reference

12 December 2020

Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone

1 reference

12 December 2020

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

1 reference

12 December 2020

Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system

1 reference

12 December 2020

Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life

1 reference

12 December 2020

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

1 reference

12 December 2020

Risperidone versus haloperidol: II. Cost-effectiveness

1 reference

12 December 2020

A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

12 December 2020

A prospective evaluation of adherence to medication in first episode schizophrenia

1 reference

12 December 2020

Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome

1 reference

12 December 2020

Pharmacological profile of risperidone

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

12 December 2020

Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia

1 reference

12 December 2020

Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics

1 reference

12 December 2020

Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia

1 reference

12 December 2020

Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder

1 reference

12 December 2020

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

1 reference

12 December 2020

Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Pharmacology and clinical experience with risperidone

1 reference

12 December 2020

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

1 reference

12 December 2020

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia

1 reference

12 December 2020

Cost comparisons of olanzapine and risperidone in treating schizophrenia

1 reference

12 December 2020

Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.

1 reference

12 December 2020

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

1 reference

12 December 2020

A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

1 reference

12 December 2020

Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics

1 reference

12 December 2020

Long-acting risperidone in stable patients with schizoaffective disorder

1 reference

12 December 2020

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

1 reference

12 December 2020

Psychiatrists' attitudes to maintenance medication for patients with schizophrenia

1 reference

12 December 2020

Dosing issues and depot medication in the maintenance treatment of schizophrenia.

1 reference

12 December 2020

Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot

1 reference

12 December 2020

1 reference

12 December 2020

Review of incidence studies of tardive dyskinesia associated with typical antipsychotics

1 reference

12 December 2020

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

12 December 2020

Tardive dyskinesias and antipsychotics: a review

1 reference

12 December 2020

Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial

1 reference

12 December 2020

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

1 reference

12 December 2020

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

1 reference

12 December 2020

An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study

1 reference

12 December 2020

Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics

1 reference

12 December 2020

Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences

1 reference

12 December 2020

Risperidone. A pharmacoeconomic review of its use in schizophrenia

1 reference

12 December 2020

Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity

1 reference

12 December 2020

The effects of atypical antipsychotics on serum prolactin levels

1 reference

12 December 2020

Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.

1 reference

12 December 2020

10.2165/00003495-200767110-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1053679805

0 references

1 reference